Dr. Mutyam received his PhD in Biology from the University of Dayton in 2012. In 2013, he joined UAB's Division of Pulmonary, Allergy, and Critical Care Medicine as a postdoctoral research fellow. In the laboratory of Dr. Steven Rowe, Dr. Mutyam investigated the role of premature stop codons in CFTR gene, representing an exciting strategy for treatment of genetic diseases caused by nonsense mutations, which are responsible for approximately 10 percent of all genetic diseases. Following his research fellow position, the division hired him as an instructor faculty in 2016. Dr. Mutyam is an active member in the American Physiological Society, a Member at Large in the Birmingham Physiology Network, an associate editor for Frontiers in Pharmacology, and an Editorial Board Member for the Journal of Pediatric Care Insight. His ongoing laboratory research is focused on understanding the basic mechanistic defects underlying ion transport in CF airway epithelial cells and its associated physiology.
Dr. Mutyam's current research focuses on identifying and testing the efficacy of novel drugs using In vitro cell culture model systems for potential treatment of genetic diseases caused by nonsense mutations. He has successfully advanced the use of high throughput screening technology to identify novel CF drugs and his initial drug screening efforts have lead to the discovery of several lead agents that has been shown restore CFTR function. Dr. Mutyam is also leading efforts to establish primary airway epithelial cells from individual Cystic Fibrosis patients with unique genetic defects as readily available laboratory models for drug screening using state-of-the-art tissue culture techniques.